DK3302431T3 - Taxanpartikler og anvendelse deraf - Google Patents

Taxanpartikler og anvendelse deraf Download PDF

Info

Publication number
DK3302431T3
DK3302431T3 DK16732387.2T DK16732387T DK3302431T3 DK 3302431 T3 DK3302431 T3 DK 3302431T3 DK 16732387 T DK16732387 T DK 16732387T DK 3302431 T3 DK3302431 T3 DK 3302431T3
Authority
DK
Denmark
Prior art keywords
taxan
particles
taxan particles
Prior art date
Application number
DK16732387.2T
Other languages
English (en)
Inventor
Michael Baltezor
Joseph Farthing
Jake Sittenauer
Jahna Espinosa
Samuel Campbell
Matthew Mcclorey
Julia K Fischer
Mark D Williams
Gary E Clapp
Original Assignee
Crititech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crititech Inc filed Critical Crititech Inc
Application granted granted Critical
Publication of DK3302431T3 publication Critical patent/DK3302431T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/02—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of powders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D46/00—Filters or filtering processes specially modified for separating dispersed particles from gases or vapours
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D46/00—Filters or filtering processes specially modified for separating dispersed particles from gases or vapours
    • B01D46/24—Particle separators, e.g. dust precipitators, using rigid hollow filter bodies
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J19/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J19/08—Processes employing the direct application of electric or wave energy, or particle radiation; Apparatus therefor
    • B01J19/10—Processes employing the direct application of electric or wave energy, or particle radiation; Apparatus therefor employing sonic or ultrasonic vibrations
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J19/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J19/26—Nozzle-type reactors, i.e. the distribution of the initial reactants within the reactor is effected by their introduction or injection through nozzles
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2/00—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic
    • B01J2/02—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic by dividing the liquid material into drops, e.g. by spraying, and solidifying the drops
    • B01J2/04—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic by dividing the liquid material into drops, e.g. by spraying, and solidifying the drops in a gaseous medium
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2/00—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic
    • B01J2/02—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic by dividing the liquid material into drops, e.g. by spraying, and solidifying the drops
    • B01J2/06—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic by dividing the liquid material into drops, e.g. by spraying, and solidifying the drops in a liquid medium
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J3/00—Processes of utilising sub-atmospheric or super-atmospheric pressure to effect chemical or physical change of matter; Apparatus therefor
    • B01J3/008—Processes carried out under supercritical conditions
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J3/00—Processes of utilising sub-atmospheric or super-atmospheric pressure to effect chemical or physical change of matter; Apparatus therefor
    • B01J3/02—Feed or outlet devices therefor
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J4/00—Feed or outlet devices; Feed or outlet control devices
    • B01J4/001—Feed or outlet devices as such, e.g. feeding tubes
    • B01J4/002—Nozzle-type elements
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05B—SPRAYING APPARATUS; ATOMISING APPARATUS; NOZZLES
    • B05B1/00—Nozzles, spray heads or other outlets, with or without auxiliary devices such as valves, heating means
    • B05B1/34—Nozzles, spray heads or other outlets, with or without auxiliary devices such as valves, heating means designed to influence the nature of flow of the liquid or other fluent material, e.g. to produce swirl
    • B05B1/3405—Nozzles, spray heads or other outlets, with or without auxiliary devices such as valves, heating means designed to influence the nature of flow of the liquid or other fluent material, e.g. to produce swirl to produce swirl
    • B05B1/341—Nozzles, spray heads or other outlets, with or without auxiliary devices such as valves, heating means designed to influence the nature of flow of the liquid or other fluent material, e.g. to produce swirl to produce swirl before discharging the liquid or other fluent material, e.g. in a swirl chamber upstream the spray outlet
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05B—SPRAYING APPARATUS; ATOMISING APPARATUS; NOZZLES
    • B05B1/00—Nozzles, spray heads or other outlets, with or without auxiliary devices such as valves, heating means
    • B05B1/34—Nozzles, spray heads or other outlets, with or without auxiliary devices such as valves, heating means designed to influence the nature of flow of the liquid or other fluent material, e.g. to produce swirl
    • B05B1/3405—Nozzles, spray heads or other outlets, with or without auxiliary devices such as valves, heating means designed to influence the nature of flow of the liquid or other fluent material, e.g. to produce swirl to produce swirl
    • B05B1/341—Nozzles, spray heads or other outlets, with or without auxiliary devices such as valves, heating means designed to influence the nature of flow of the liquid or other fluent material, e.g. to produce swirl to produce swirl before discharging the liquid or other fluent material, e.g. in a swirl chamber upstream the spray outlet
    • B05B1/3489—Nozzles having concentric outlets
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05B—SPRAYING APPARATUS; ATOMISING APPARATUS; NOZZLES
    • B05B13/00—Machines or plants for applying liquids or other fluent materials to surfaces of objects or other work by spraying, not covered by groups B05B1/00 - B05B11/00
    • B05B13/02—Means for supporting work; Arrangement or mounting of spray heads; Adaptation or arrangement of means for feeding work
    • B05B13/0278—Arrangement or mounting of spray heads
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2271/00—Sealings for filters specially adapted for separating dispersed particles from gases or vapours
    • B01D2271/02—Gaskets, sealings
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2204/00—Aspects relating to feed or outlet devices; Regulating devices for feed or outlet devices
    • B01J2204/002—Aspects relating to feed or outlet devices; Regulating devices for feed or outlet devices the feeding side being of particular interest
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05D—PROCESSES FOR APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05D2401/00—Form of the coating product, e.g. solution, water dispersion, powders or the like
    • B05D2401/90—Form of the coating product, e.g. solution, water dispersion, powders or the like at least one component of the composition being in supercritical state or close to supercritical state
DK16732387.2T 2015-06-04 2016-06-06 Taxanpartikler og anvendelse deraf DK3302431T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562171008P 2015-06-04 2015-06-04
US201562171060P 2015-06-04 2015-06-04
US201562171001P 2015-06-04 2015-06-04
PCT/US2016/035993 WO2016197091A1 (en) 2015-06-04 2016-06-06 Taxane particles and their use

Publications (1)

Publication Number Publication Date
DK3302431T3 true DK3302431T3 (da) 2020-11-30

Family

ID=56194575

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16732387.2T DK3302431T3 (da) 2015-06-04 2016-06-06 Taxanpartikler og anvendelse deraf

Country Status (14)

Country Link
US (11) US9814685B2 (da)
EP (4) EP3302431B1 (da)
JP (5) JP6758325B2 (da)
KR (5) KR20200134347A (da)
CN (4) CN107683174B (da)
AU (3) AU2016270558B2 (da)
CA (3) CA3026452C (da)
DK (1) DK3302431T3 (da)
ES (1) ES2833749T3 (da)
HK (3) HK1253021B (da)
PT (1) PT3302431T (da)
RU (1) RU2750163C2 (da)
SG (2) SG10201913947RA (da)
WO (3) WO2016197101A1 (da)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3302431B1 (en) 2015-06-04 2020-11-11 Crititech, Inc. Taxane particles and their use
CA2998483C (en) 2015-09-16 2022-09-06 Dfb Soria, Llc Delivery of drug nanoparticles and methods of use thereof
CN109475492B (zh) 2016-04-04 2022-04-29 克里蒂泰克公司 实体肿瘤治疗方法
CN108602258B (zh) * 2016-05-12 2022-02-22 惠普发展公司有限责任合伙企业 构建材料容器
WO2018170210A1 (en) 2017-03-15 2018-09-20 Dfb Soria, Llc Topical therapy for the treatment of vulvar intraepithelial neoplasia (vin) and genital warts using nanoparticles of taxanes
WO2018170207A1 (en) 2017-03-15 2018-09-20 Dfb Soria, Llc Topical therapy for the treatment of skin keratoses using nanoparticles of taxanes
ES2955884T3 (es) 2017-03-15 2023-12-07 Dfb Soria Llc Terapia tópica para el tratamiento de malignidades de la piel con nanoparticulas de taxanos
JP2020523285A (ja) 2017-06-09 2020-08-06 クリチテック，インコーポレイテッド 抗腫瘍粒子の嚢胞内注入による上皮嚢胞の治療
SG11201909837YA (en) * 2017-06-14 2019-11-28 Crititech Inc Methods for treating lung disorders
EP3648741A4 (en) * 2017-07-07 2021-05-05 DFB Pharmaceuticals, LLC TREATMENT OF HYPERPLASTIC TISSUE GROWTH INCLUDING BENEFIT PROSTATE HYPERPLASIA (BPH) BY DIRECT INJECTION OF ANTINEOPLASTIC AGENT
US11931368B2 (en) 2017-09-29 2024-03-19 Crititech, Inc. Glucocorticoid “nintedanib” particles and their use
EP3687977A1 (en) 2017-09-29 2020-08-05 Crititech, Inc. Ciprofloxacin polymorph and its use
CN111278436A (zh) * 2017-10-03 2020-06-12 克里蒂泰克公司 局部递送抗肿瘤颗粒与全身递送免疫治疗剂相结合用于治疗癌症
US20190209515A1 (en) * 2018-01-05 2019-07-11 Crititech, Inc. Treatment of Bladder Cancer by Intratumoral Injection of Taxane Particles
US11497726B2 (en) 2018-03-16 2022-11-15 Dfb Soria, Ll. Topical therapy for the treatment of cervical intraepithelial neoplasia (CIN) and cervical cancer using nanoparticles of taxanes
WO2019231499A1 (en) 2018-05-31 2019-12-05 Crititech, Inc. Use of antineoplastic agents to stimulate the immune system for treatment of cancer
KR20210016511A (ko) * 2018-05-31 2021-02-16 크리티테크, 인크. 입양 세포 요법 및 암 백신을 위한 종양 특이적 면역 세포를 대상체로부터 단리하는 방법
WO2019231498A1 (en) 2018-05-31 2019-12-05 Crititech, Inc. Treatment of kidney tumors by intratumoral injection of taxane particles
CN108970835B (zh) * 2018-09-20 2020-11-17 马鞍山纽泽科技服务有限公司 一种耐高温喷射装置
WO2020072090A1 (en) 2018-10-03 2020-04-09 Crititech, Inc. Use of antineoplastic agents to stimulate the immune system for production of tertiary lymphoid structures (tls)
US11911499B2 (en) 2019-11-07 2024-02-27 Resurge Therapeutics, Inc. System and method for prostate treatment
CN115297857A (zh) * 2020-02-04 2022-11-04 珠海贝海生物技术有限公司 多西他赛制剂
KR20230044423A (ko) 2020-07-23 2023-04-04 크리티테크, 인크. 라파티닙 입자 및 이의 용도
US20220241257A1 (en) * 2020-07-23 2022-08-04 Crititech, Inc. Sorafenib particles and uses thereof
CN113447635B (zh) * 2021-05-11 2023-09-29 江西农业大学 一种盆栽类土壤不同深度温室气体释放速率测定装置
WO2023086779A1 (en) 2021-11-10 2023-05-19 Crititech, Inc. Niraparib particles and uses thereof
US11738029B2 (en) 2021-11-10 2023-08-29 Crititech, Inc. Rucaparib particles and uses thereof
US11957654B2 (en) 2022-01-29 2024-04-16 Resurge Therapeutics, Inc. Treating benign prostatic hyperplasia
US11974979B2 (en) 2022-01-29 2024-05-07 Resurge Therapeutics, Inc. Treatments for benign prostatic hyperplasia

Family Cites Families (154)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3648698A (en) * 1969-05-23 1972-03-14 George O Doherty Surgical collection unit
DE3120047C2 (de) * 1981-05-20 1984-03-29 Sterimed Gesellschaft für medizinischen Bedarf mbH, 6600 Saarbrücken Sauggerät zum Ansaugen von Körpersekreten
JPS5958019U (ja) 1982-10-08 1984-04-16 松下電器産業株式会社 電気集塵機
US4780138A (en) * 1986-10-27 1988-10-25 Bodine Albert G Sonic apparatus and method for facilitating the extraction of minerals from ore in a leachant
US5143528A (en) 1990-02-14 1992-09-01 Challenge Industries Lint collector
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
WO1999000113A1 (en) 1997-06-27 1999-01-07 Vivorx Pharmaceuticals, Inc. Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US5409833A (en) * 1993-07-01 1995-04-25 Baxter International Inc. Microvessel cell isolation apparatus
GB9313642D0 (en) * 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
GB9413202D0 (en) 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
US5626862A (en) 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
US5480540A (en) * 1994-10-17 1996-01-02 General Electric Company Spray apparatus for separating solids from fluids
US5874481A (en) 1995-06-07 1999-02-23 Alliance Pharmaceutical Corp. Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents
US5833891A (en) 1996-10-09 1998-11-10 The University Of Kansas Methods for a particle precipitation and coating using near-critical and supercritical antisolvents
US5874029A (en) 1996-10-09 1999-02-23 The University Of Kansas Methods for particle micronization and nanonization by recrystallization from organic solutions sprayed into a compressed antisolvent
US6495579B1 (en) 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
CA2628857C (en) 1996-12-30 2011-09-13 Batelle Memorial Institute Formulation and method for treating neoplasms by inhalation
US6117949A (en) 1998-10-01 2000-09-12 Macromed, Inc. Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
JPH11189403A (ja) 1997-12-25 1999-07-13 Tic:Kk 層構造型複合粒子製造装置
JP3418751B2 (ja) 1998-01-22 2003-06-23 参天製薬株式会社 フルオロメトロン懸濁型点眼剤
IL131217A0 (en) 1998-03-10 2001-01-28 Napro Biotherapeutics Inc Novel methods and compositions for delivery of taxanes
US6221153B1 (en) 1998-06-09 2001-04-24 Trevor Percival Castor Method for producing large crystals of complex molecules
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
US6113795A (en) 1998-11-17 2000-09-05 The University Of Kansas Process and apparatus for size selective separation of micro- and nano-particles
DK1131063T3 (da) 1998-11-25 2003-07-21 Universitaetsklinikum Freiburg Hyperforinsalve eller -creme
US6537585B1 (en) 1999-03-26 2003-03-25 Guilford Pharmaceuticals, Inc. Methods and compositions for treating solid tumors
US7217735B1 (en) 1999-04-09 2007-05-15 Au Jessie L-S Methods and compositions for enhancing delivery of therapeutic agents to tissues
JP4722295B2 (ja) * 1999-05-27 2011-07-13 エイカスフィアー・インコーポレーテッド 多孔性薬剤マトリクスおよびその製造方法
US6610317B2 (en) 1999-05-27 2003-08-26 Acusphere, Inc. Porous paclitaxel matrices and methods of manufacture thereof
US6858199B1 (en) 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
US6616849B1 (en) 1999-08-25 2003-09-09 Shimadzu Corporation Method of and system for continuously processing liquid materials, and the product processed thereby
WO2001036007A2 (en) 1999-11-12 2001-05-25 Angiotech Pharmaceuticals, Inc. Compositions of a combination of radioactive therapy and cell-cycle inhibitors
SE515604C2 (sv) * 2000-04-28 2001-09-10 Bst Ab Förfarande och anordning för uppsugning och transport av vätskor, företrädesvis blod
US6620351B2 (en) 2000-05-24 2003-09-16 Auburn University Method of forming nanoparticles and microparticles of controllable size using supercritical fluids with enhanced mass transfer
US6562952B1 (en) 2000-10-31 2003-05-13 The University Of Kansas Precipitation of proteins from organic solutions
US20020081339A1 (en) 2000-12-22 2002-06-27 Philippe Menei Treatment of inoperable tumors by stereotactic injection of microspheres
US20020192280A1 (en) 2001-05-01 2002-12-19 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating inflammatory conditions utilizing protein or polysaccharide containing anti-microtubule agents
EP1401563B2 (en) 2001-07-02 2015-09-16 Micro & Nano Materials SAGL Process for the production of micro and/or nano particles
US20030054042A1 (en) 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
US20030134810A1 (en) 2001-10-09 2003-07-17 Chris Springate Methods and compositions comprising biocompatible materials useful for the administration of therapeutic agents
CN1592607A (zh) 2001-10-15 2005-03-09 克里蒂泰克公司 水溶性差药物的组合物、其给药方法和治疗方法
US20030166509A1 (en) 2001-11-20 2003-09-04 Advanced Inhalation Research, Inc. Compositions for sustained action product delivery and methods of use thereof
US7138136B2 (en) 2002-03-05 2006-11-21 Cleveland State University Agglomerated particles for aerosol drug delivery
JP2003251127A (ja) 2002-03-06 2003-09-09 Kazuo Hirakawa 集塵装置
CA2479665C (en) 2002-03-20 2011-08-30 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
GB2387781A (en) * 2002-04-25 2003-10-29 Nektar Therapeutics Uk Ltd Particulate materials
EA200401250A1 (ru) 2002-04-26 2005-06-30 Тева Фармасьютикал Индастриес Лтд. Фармацевтические композиции на основе микрочастиц для внутриопухолевого введения
US9339459B2 (en) * 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
CN1255394C (zh) 2002-06-24 2006-05-10 成都思摩纳米技术有限公司 紫杉醇纳米微粒的制备方法及应用
KR100573289B1 (ko) 2002-07-20 2006-04-24 대화제약 주식회사 방광내 투여를 통한 방광암치료용 파클리탁셀 조성물 및그의 제조 방법
US6916389B2 (en) * 2002-08-13 2005-07-12 Nanotechnologies, Inc. Process for mixing particulates
CN2578811Y (zh) * 2002-10-24 2003-10-08 陆纪清 全闭式煤粉取样装置
EP1569620A4 (en) * 2002-10-30 2006-03-22 Spherics Inc NANOPARTICULAR BIOACTIVE AGENTS
KR100508518B1 (ko) * 2002-11-13 2005-08-17 한미약품 주식회사 초임계유체 공정을 이용한 파클리탁셀 고체분산체의 제조방법 및 이 방법으로 제조된 파클리탁셀 고체분산체
TR200502189T1 (tr) 2002-12-09 2007-01-22 American Bioscience, Inc. Kompozisyonlar ve farmakolojik etken maddelerin aktarımı için yöntemler.
US7455797B2 (en) 2003-02-28 2008-11-25 Ferro Corporation Method and apparatus for producing particles using supercritical fluid
WO2004089291A2 (en) 2003-04-03 2004-10-21 Au Jessie L-S Tumor-targeting drug-loaded particles
US20060147535A1 (en) 2003-04-16 2006-07-06 Poongunran Muthukumaran Methods for and compositions of anticancer medicaments
US20050059613A1 (en) 2003-07-08 2005-03-17 Bahram Memarzadeh Compositions and methods for the enhanced uptake of therapeutic agents through the bladder epithelium
US8021831B2 (en) 2003-08-25 2011-09-20 Board Of Regents, The University Of Texas System Taxane chemosensitivity prediction test
JP2007001865A (ja) 2003-09-16 2007-01-11 Ltt Bio-Pharma Co Ltd 脂溶性薬物封入微粒子、その製造法およびそれを含有する製剤
HUE028648T2 (en) 2003-10-15 2016-12-28 Syncore Biotechnology Co Ltd Use of cationic liposomes containing paclitaxel
TWI371274B (en) * 2003-10-23 2012-09-01 Bristol Myers Squibb Co Process for making sterile aripiprazole of desired mean particle size
US7208106B2 (en) 2003-10-24 2007-04-24 Ferro Corporation Method of forming particles
ES2366646T3 (es) 2003-11-05 2011-10-24 Elan Pharma International Limited Composiciones en forma de nanopartículas que tienen un péptido como estabilizante superficial.
DE10357091A1 (de) * 2003-12-06 2005-07-07 Degussa Ag Vorrichtung und Verfahren zur Abscheidung feinster Partikel aus der Gasphase
GB0402963D0 (en) 2004-02-11 2004-03-17 Univ Nottingham Counter current mixing device for two different fluids
US8043631B2 (en) 2004-04-02 2011-10-25 Au Jessie L S Tumor targeting drug-loaded particles
JP5164381B2 (ja) 2004-10-29 2013-03-21 株式会社奈良機械製作所 微細粒子の造粒方法
CA2588442A1 (en) 2004-12-14 2006-06-29 Transave, Inc. Lipid particles comprising bioactive agents, methods of preparing and uses thereof
ES2265262B1 (es) 2005-01-31 2008-03-01 Activery Biotech, S.L.(Titular Al 50%) Procedimiento para la obtencion de sistemas micro- y nanodispersos.
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
BRPI0608173A2 (pt) * 2005-02-24 2010-11-09 Elan Pharma Int Ltd composição, uso da mesma, e, método de produzir uma composição de docetaxel nanoparticulada ou análogo do mesmo
US7872050B2 (en) 2005-03-14 2011-01-18 Yaupon Therapeutics Inc. Stabilized compositions of volatile alkylating agents and methods of using thereof
US8118795B2 (en) * 2005-03-22 2012-02-21 Medindica-Pak, Inc Disposal chain supply systems method and apparatus
PL1865924T3 (pl) 2005-03-31 2016-06-30 Lidds Ab Sposób leczenia chorób gruczołu krokowego oparty na miejscowym dostarczaniu substancji czynnych
CN1923189A (zh) 2005-08-30 2007-03-07 孔庆忠 一种紫杉碱类抗癌药物的缓释注射剂
NZ592132A (en) 2005-08-31 2012-12-21 Abraxis Bioscience Llc Composition comprising nanoparticles of docitaxel and a citrate
EA013089B1 (ru) 2005-12-11 2010-02-26 Скф Технолоджис А/С Получение наноразмерных материалов
US8906392B2 (en) 2005-12-16 2014-12-09 University Of Kansas Nanocluster compositions and methods
AR054215A1 (es) * 2006-01-20 2007-06-13 Eriochem Sa Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit
CN101336899A (zh) 2006-01-25 2009-01-07 济南帅华医药科技有限公司 含紫杉烷的抗癌缓释注射剂
JP5216601B2 (ja) 2006-03-14 2013-06-19 リッズ エービー 生体吸収性の制御放出組成物
US7964029B2 (en) * 2006-07-17 2011-06-21 Thar Instrument, Inc. Process flowstream collection system
WO2008044092A1 (en) * 2006-10-11 2008-04-17 Renault Trucks Truck provided with a passive keyless access system
EP2077823B1 (en) 2006-10-11 2012-06-27 Crititech, Inc. Method for precipitation of small medicament particles into use containers
TWI405590B (zh) 2007-04-06 2013-08-21 Activus Pharma Co Ltd 微粉碎化有機化合物粒子之製法
EP3326630A3 (en) 2007-05-03 2018-08-29 Abraxis BioScience, LLC Methods and compositions for treating pulmonary hypertension
US20100197944A1 (en) 2007-07-04 2010-08-05 Dr. Reddy's Laboratories Limited Docetaxel process and polymorphs
CN101129338A (zh) * 2007-08-27 2008-02-27 四川大学 超临界流体新技术微细化抗癌药物紫杉醇
CA2716662A1 (en) 2008-03-06 2009-03-11 Nitto Denko Corporation Polymer paclitaxel conjugates and methods for treating cancer
US9056955B2 (en) * 2008-03-24 2015-06-16 Sanyo Chemical Industries, Ltd. Resin particle comprising microparticle made of a crystalline resin, and method for producing the same
RU2535017C2 (ru) 2008-09-19 2014-12-10 Активус Фарма Ко., Лтд. Композитный порошок из органического вещества для применения в медицине, способ его получения и его суспензия
CA2745238A1 (en) 2008-12-02 2010-06-10 Biocompatibles Uk Limited Pancreatic tumour treatment
PT104693B (pt) 2009-07-27 2011-11-24 Univ Lisboa Nanopartículas lipídicas semi-sólidas contendo um agente antineoplásico e seu processo de preparação
RU2012111349A (ru) 2009-08-24 2013-10-27 Байлор Колледж Оф Медсин Генерация линий ctl со специфичностью против множества опухолевых антигенов или множества вирусов
US20110209578A1 (en) * 2010-02-26 2011-09-01 Kuniaki Ara Nanoparticle manufacturing device and nanoparticle manufacturing method and method of manufacturing nanoparticle-dispersed liquid alkali metal
CN101829061A (zh) 2010-05-14 2010-09-15 无锡纳生生物科技有限公司 一种紫杉醇纳米颗粒组合物及其制备方法
NZ708506A (en) 2010-06-02 2016-08-26 Abraxis Bioscience Llc Methods of treating bladder cancer
WO2012039602A1 (en) 2010-09-21 2012-03-29 Universiteit Utrecht Holding B.V. Tunable, biodegradable linker molecules for transient conjugation of components in drug delivery systems, and drug delivery systems prepared therewith
JP2014504260A (ja) 2010-10-15 2014-02-20 グラクソ グループ リミテッド 集合ナノ粒子状薬物製剤、その製造及び使用
BR112013010575A2 (pt) * 2010-10-29 2016-08-09 Velico Medical Inc conjunto de secagem por atomização, câmara de secagem por atomização, conjunto de cabeça de secagem por atomização, dispositivo de coleta de secagem por atomização, e, método para secar por atomização um líquido
US20120177910A1 (en) * 2011-01-11 2012-07-12 Boston Scientific Scimed, Inc. Coated Medical Devices
CN104053432A (zh) 2011-04-20 2014-09-17 悉尼大学 一种实体肿瘤的治疗方法
WO2013052158A2 (en) 2011-04-26 2013-04-11 William Marsh Rice University Targeted nanovectors and their use for treatment of brain tumors
CN107095863A (zh) 2011-06-17 2017-08-29 博格有限责任公司 可吸入药物组合物
US10632131B2 (en) 2011-06-27 2020-04-28 Cristal Delivery B.V. Controlled release system
US11766459B2 (en) * 2011-07-08 2023-09-26 Jointechlabs, Inc. System and methods for preparation of adipose-derived stem cells
EP2750789B1 (en) * 2011-08-31 2018-07-11 Archer Daniels Midland Co. Spray oxidation process for producing 2,5-furandicarboxylic acid from hydroxymethylfurfural
FR2980683B1 (fr) 2011-09-30 2014-11-21 Univ Paris Curie Dispositif de guidage d'un instrument medical insere dans une voie naturelle ou une voie artificielle d'un patient
CN102319898B (zh) * 2011-10-13 2013-05-08 西北工业大学 一种制备合金及金属基复合材料零部件的喷射成形系统
CN102488682A (zh) 2011-11-22 2012-06-13 四川九章生物化工科技发展有限公司 绿原酸的抗癌新用途
JP2013212494A (ja) * 2012-03-05 2013-10-17 Ricoh Co Ltd 樹脂微粒子の製造方法
US10555911B2 (en) 2012-05-04 2020-02-11 Yale University Highly penetrative nanocarriers for treatment of CNS disease
CN102728414A (zh) * 2012-07-07 2012-10-17 中山大学 用于制备单壁碳纳米管的催化剂的制备方法及其运用
TW201408304A (zh) 2012-08-31 2014-03-01 Cathay General Hospital 一種合併抗癌藥物及荷爾蒙之抗腎細胞癌藥物及其製造方法
WO2014046983A1 (en) 2012-09-21 2014-03-27 Intensity Therapeutic Method of treating cancer
WO2014081881A2 (en) * 2012-11-20 2014-05-30 Andrew Paul Joseph Fluid-based extractor
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
WO2014132163A1 (en) 2013-02-28 2014-09-04 Pfizer Inc. Enhanced stability of novel liquid compositions
US8778181B1 (en) 2013-03-14 2014-07-15 Crititech, Inc. Equipment assembly for and method of processing particles
US9925512B2 (en) 2013-03-14 2018-03-27 Crititech, Inc. Equipment assembly for and method of processing particles
EP2978420A4 (en) 2013-03-28 2016-12-21 Bbs Nanotechnology Ltd STABLE NANOCOMPOSITION COMPRISING PACLITAXEL, PROCESS FOR ITS PREPARATION, USE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
US9301926B2 (en) 2013-04-10 2016-04-05 Massachusetts Institute Of Technology Local drug delivery devices and methods for treating cancer
CN203699094U (zh) * 2013-10-15 2014-07-09 雷海平 新式垃圾桶及配套内桶
EP3057619A1 (en) 2013-10-16 2016-08-24 Université Libre de Bruxelles Formulations useful in the treatment of proliferative diseases affecting the respiratory tract
AU2014364601A1 (en) 2013-12-17 2016-07-07 Genentech, Inc. Methods of treating HER2-positive cancers using PD-1 axis binding antagonists and anti-HER2 antibodies
KR20230076867A (ko) 2013-12-20 2023-05-31 더 브로드 인스티튜트, 인코퍼레이티드 신생항원 백신과의 병용 요법
WO2015103005A1 (en) 2014-01-03 2015-07-09 Research Institute At Nationwide Children's Hospital Amphiphilic amine compounds and their use as therapeutic agents and nanocarriers
CN203737192U (zh) * 2014-01-20 2014-07-30 四川西汉电子科技有限责任公司 一种造粒机
TWI601542B (zh) 2014-04-18 2017-10-11 林信湧 一種用於治療肺癌之吸入式醫藥組成物及其備製方法
WO2015187194A1 (en) 2014-06-01 2015-12-10 Crititech, Inc. Use of paclitaxel particles
CN203847940U (zh) * 2014-06-04 2014-09-24 刘希 一种加料喷嘴调节支架
WO2015191590A2 (en) 2014-06-09 2015-12-17 Biomed Valley Discoveries, Inc. Combination therapies targeting tumor-associated stroma or tumor cells and microtubules
US9533449B2 (en) * 2014-06-19 2017-01-03 Autodesk, Inc. Material deposition systems with four or more axes
EP3234193B1 (en) 2014-12-19 2020-07-15 Massachusetts Institute of Technology Molecular biomarkers for cancer immunotherapy
EP3302431B1 (en) * 2015-06-04 2020-11-11 Crititech, Inc. Taxane particles and their use
CA2998483C (en) * 2015-09-16 2022-09-06 Dfb Soria, Llc Delivery of drug nanoparticles and methods of use thereof
CA2995029C (en) 2015-09-25 2022-10-25 Zy Therapeutics Inc. Drug formulation based on particulates comprising polysaccharide-vitamin conjugate
DE202016006620U1 (de) 2015-10-28 2017-04-12 Qass Gmbh Vorrichtungen zum Beobachten eines Magnetfelds eines Materialvolumens
CN116376826A (zh) 2016-01-20 2023-07-04 菲特治疗公司 用来在过继性免疫疗法中进行免疫细胞调节的组合物和方法
CN109475492B (zh) * 2016-04-04 2022-04-29 克里蒂泰克公司 实体肿瘤治疗方法
CN107281502B (zh) 2016-04-05 2021-05-04 上海市肿瘤研究所 一种复合显影温敏凝胶栓塞剂、制备方法及其应用
US10894093B2 (en) 2016-04-15 2021-01-19 Cellectis Method of engineering drug-specific hypersensitive t-cells for immunotherapy by gene inactivation
US10160159B2 (en) * 2016-05-12 2018-12-25 Hewlett-Packard Development Company, L.P. Build material container
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
EP3506942B1 (en) 2016-09-01 2022-11-16 Mayo Foundation for Medical Education and Research Carrier-pd-l1 binding agent compositions for treating cancers
WO2018170207A1 (en) 2017-03-15 2018-09-20 Dfb Soria, Llc Topical therapy for the treatment of skin keratoses using nanoparticles of taxanes
WO2018170210A1 (en) 2017-03-15 2018-09-20 Dfb Soria, Llc Topical therapy for the treatment of vulvar intraepithelial neoplasia (vin) and genital warts using nanoparticles of taxanes
ES2955884T3 (es) 2017-03-15 2023-12-07 Dfb Soria Llc Terapia tópica para el tratamiento de malignidades de la piel con nanoparticulas de taxanos
JP2020523285A (ja) 2017-06-09 2020-08-06 クリチテック，インコーポレイテッド 抗腫瘍粒子の嚢胞内注入による上皮嚢胞の治療
SG11201909837YA (en) 2017-06-14 2019-11-28 Crititech Inc Methods for treating lung disorders

Also Published As

Publication number Publication date
RU2017140678A3 (da) 2019-07-17
AU2016270549A1 (en) 2017-11-16
AU2016270558B2 (en) 2020-08-13
PT3302431T (pt) 2020-11-30
US20160354336A1 (en) 2016-12-08
RU2750163C2 (ru) 2021-06-22
EP3838264A1 (en) 2021-06-23
KR102317107B1 (ko) 2021-10-25
CN107683131B (zh) 2021-09-28
US20160374953A1 (en) 2016-12-29
AU2016270559A1 (en) 2017-11-16
US10993927B2 (en) 2021-05-04
KR102551708B1 (ko) 2023-07-06
AU2016270549B2 (en) 2019-01-17
US10729673B2 (en) 2020-08-04
HK1253021B (zh) 2020-01-24
KR20200020995A (ko) 2020-02-26
SG10201913945QA (en) 2020-03-30
CN107683131A (zh) 2018-02-09
KR102077518B1 (ko) 2020-02-14
US9814685B2 (en) 2017-11-14
JP2022121532A (ja) 2022-08-19
US9918957B2 (en) 2018-03-20
JP6892394B2 (ja) 2021-06-23
CA3026454A1 (en) 2016-12-08
EP3302431B1 (en) 2020-11-11
AU2016270558A1 (en) 2017-11-16
EP3302423A1 (en) 2018-04-11
US10751319B2 (en) 2020-08-25
US10507195B2 (en) 2019-12-17
EP3302423B1 (en) 2022-05-25
KR102337080B1 (ko) 2021-12-08
SG10201913947RA (en) 2020-03-30
KR20200134347A (ko) 2020-12-01
US20210393569A1 (en) 2021-12-23
US11123322B2 (en) 2021-09-21
RU2017140678A (ru) 2019-07-09
EP3302780A1 (en) 2018-04-11
US20180125783A1 (en) 2018-05-10
US20200163928A1 (en) 2020-05-28
JP2020203913A (ja) 2020-12-24
CA2988132A1 (en) 2016-12-08
JP2018526188A (ja) 2018-09-13
US20170224650A1 (en) 2017-08-10
JP2018524145A (ja) 2018-08-30
CA3026452C (en) 2023-03-21
JP6921759B2 (ja) 2021-08-18
ES2833749T3 (es) 2021-06-15
CN107683174A (zh) 2018-02-09
WO2016197091A1 (en) 2016-12-08
CN107743418A (zh) 2018-02-27
JP6758325B2 (ja) 2020-09-23
WO2016197101A1 (en) 2016-12-08
CN107683174B (zh) 2021-02-19
US11291646B2 (en) 2022-04-05
HK1253020A1 (zh) 2019-06-06
EP3302780B1 (en) 2019-04-17
CN114010628A (zh) 2022-02-08
JP2018516907A (ja) 2018-06-28
HK1253018A1 (zh) 2019-06-06
KR20180015635A (ko) 2018-02-13
HK1253021A1 (zh) 2019-06-06
KR20180016366A (ko) 2018-02-14
AU2016270559B2 (en) 2020-12-10
CA2988132C (en) 2021-04-27
US20180116910A1 (en) 2018-05-03
EP3302431A1 (en) 2018-04-11
JP7096299B2 (ja) 2022-07-05
BR112017025815A2 (pt) 2018-08-14
US20200101039A1 (en) 2020-04-02
CA3026452A1 (en) 2016-12-08
CA3026454C (en) 2023-07-04
KR20180013906A (ko) 2018-02-07
WO2016197100A1 (en) 2016-12-08
US20200405684A1 (en) 2020-12-31
US20180169058A1 (en) 2018-06-21
US20210000786A1 (en) 2021-01-07

Similar Documents

Publication Publication Date Title
DK3302431T3 (da) Taxanpartikler og anvendelse deraf
DK3448386T3 (da) Isoquinolin-3-ylcarboxamider og fremstilling og anvendelse deraf
DK3303379T3 (da) Tigit-bindende midler og anvendelser deraf
DK3480213T3 (da) Syntac-polypeptider og anvendelser deraf
DK3237418T3 (da) Triazolopyrimidinforbindelser og anvendelser deraf
DK3268470T3 (da) Transposasepolypeptider og anvendelser deraf
DK3229838T3 (da) Anti-C10orf54-antistoffer og anvendelser deraf
DK3126388T3 (da) Anti-EGFRvIII-antistoffer og anvendelser deraf
DK3452463T3 (da) Amidsubstituerede pyridinyltriazolderivater og anvendelser deraf
DK3210977T3 (da) Hidtil ukendt aminoalkylbenzothiazepinderivat og anvendelse deraf
DK3212255T3 (da) Selvorienterende sprøjte og sprøjtegrænseflade
DK3235830T3 (da) Interleukin-15-proteinkompleks og anvendelse deraf
DK3189081T3 (da) Cd123-bindende midler og anvendelser deraf
DK3215147T3 (da) Neurodæmpende norketamin-forbindelser og fremgangsmåder
DK3218358T3 (da) Ifluorometyl-aminopyridiner og difluorometyl-aminopyrimidiner
DK3015526T3 (da) Hydrofluorolefinbaseret sammensætning og anvendelse deraf
DK3193611T3 (da) Mk2-inhibitorer og anvendelser deraf
DK3161139T3 (da) Tlr-4-specifikke aptamerer og anvendelser heraf
DK3265641T3 (da) Stigørenhed og fremgangsmåde
DK3269809T3 (da) MODIFICERET AMINOACYL-tRNA-SYNTETASE OG ANVENDELSE DERAF
DK3209773T3 (da) Prolintolerante tripeptidylpeptidaser og anvendelser deraf
DK3236991T3 (da) Fgf21-derivater og anvendelser deraf
DK3201317T3 (da) Biomarkører for rheumatoid arthritis og anvendelse deraf
DK3233105T3 (da) Hidtil ukendt kombination og anvendelse
DK3417058T3 (da) Sortase-modificerede molekyler og anvendelser deraf